为进一步明确食管癌患者治疗前那不勒斯预后评分（NPS）的预测价值，该评分根据血清白蛋白浓度、总胆固醇水平、中性粒细胞与淋巴细胞比值（NLR）和淋巴细胞与单核细胞比值（LMR）进行计算。检索截至2023年12月1日的PubMed、EMBASE、Web of Science和CNKI数据库中的相关研究。总生存期 (OS)、无进展生存期 (PFS) 和癌症特异性生存期 (CSS) 是终点，结合风险比 (HR) 和 95% 置信区间 (CI) 来评估 NPS 对生存的预测作用。根据病理类型和治疗进一步进行亚组分析。我们的分析纳入了10项回顾性研究，共2250例病例。汇总结果表明，较高的治疗前 NPS 预测较差的 OS（HR = 2.24，95% CI：1.57-3.20，P < .001）、PFS（HR = 3.03，95% CI：1.84-4.98，P < .001）和 CSS （HR = 2.90，95% CI：1.80-4.68，P < .001）。然后进一步按病理类型（鳞状细胞癌与食管癌）和治疗（手术与非手术）分层进行 OS 和 PFS 亚组分析，结果相似。治疗前 NPS 与食管癌和食管癌的预后显着相关。 NPS 越高，食管癌患者的生存期越差。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

To further clarify the predictive value of pretreatment Naples prognostic score (NPS), calculating based on the serum albumin concentration, total cholesterol level, neutrophil to lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR), among esophageal cancer patients based on available evidence.The PubMed, EMBASE, Web of Science and CNKI databases were searched up to December 1, 2023 for relevant studies. Overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS) were endpoints and the hazard ratio (HR) with 95% confidence interval (CI) was combined to evaluate the predictive role of NPS for survival. Subgroup analysis based on pathological type and treatment were further conducted.Ten retrospective studies with 2250 cases were included in our analysis. Pooled results demonstrated that higher pretreatment NPS predicted poorer OS (HR = 2.24, 95% CI: 1.57-3.20, P < .001), PFS (HR = 3.03, 95% CI: 1.84-4.98, P < .001) and CSS (HR = 2.90, 95% CI: 1.80-4.68, P < .001). Then subgroup analysis for the OS and PFS stratified by the pathological type (squamous cell carcinoma vs esophageal cancer) and treatment (surgery vs non-surgery) were further conducted, which showed similar results.Pretreatment NPS is significantly associated with prognosis in esophageal cancer and higher NPS predicts worse survival among patients with esophageal cancer.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.